用于治疗皮肤病的低剂量纳尔特雷:临床综述
Maggie H Zhou1, Dirk M Elston2, Brian W Morrison3
1Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
Journal of the American Academy of Dermatology
|September 17, 2025
概括
低剂量纳勒 (LDN) 通过调节阿片类和非阿片类受体,为各种自身免疫和炎症性皮肤疾病提供抗炎益处. 它在改善疾病严重程度和症状方面表现有前途,副作用比标准剂量少.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 纳尔特雷克松是一种阿片类受体对抗剂,用于低剂量 (1-5毫克) 治疗炎症和自身免疫性疾病.
- 低剂量纳尔特雷克松 (LDN) 暂时阻断阿片类受体,调高连接体/受体表达和调低炎症介质.
- 此外,LDN也对抗通关类受体4的作用,有助于其抗炎作用.
研究的目的:
- 审查低剂量纳尔特雷 (LDN) 在炎症性皮肤病症中的最新临床用途.
- 讨论相关的副作用,成本障碍,并将LDN与标准的纳尔特雷剂量进行比较.
- 为了突出LDN在治疗各种皮肤病的有效性.
主要方法:
- 临床审查低剂量纳尔特雷 (LDN) 在皮肤病学中的应用.
- 分析LDN的作用机制,包括阿片类和非阿片类受体相互作用.
- 评估报告的有效性,副作用和LDN的访问障碍.
主要成果:
- LDN在治疗皮肤病症,如牛皮,平坦和补充性胆核炎方面表现出有效性.
- 观察到疾病严重程度,身体表面区域参与和相关症状的改善.
- 与标准的纳尔特雷克松剂量相比,LDN报告的副作用较少.
结论:
- 低剂量纳尔特雷 (LDN) 是一种适用于特定皮肤病的可行的抗炎药物.
- 需要进一步的研究来优化LDN剂量和管理策略.
- 复杂的药房访问可能会成为LDN治疗的障碍.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
01:26Nephrotic Syndrome II : Assessment and Medical Management
203
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
203
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439
01:17Drugs for Treatment of Diarrhea-Predominant IBS
635
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
635
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
01:29Drugs for Treatment of Ulcerative Colitis in IBD
463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463